Other analysts also recently issued reports about the company. ValuEngine raised Allergan from a strong sell rating to a sell rating in a research report on Tuesday, May 7th. Royal Bank of Canada cut their price objective on Allergan from $165.00 to $140.00 and set a sector perform rating for the company in a research report on Wednesday, May 8th. UBS Group cut their price objective on Allergan from $173.00 to $172.00 and set a buy rating for the company in a research report on Thursday, May 9th. Mizuho reissued a buy rating and set a $194.00 price objective on shares of Allergan in a research report on Wednesday, April 24th. Finally, Raymond James cut their price objective on Allergan from $181.00 to $166.00 and set an outperform rating for the company in a research report on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $175.30.
Shares of NYSE:AGN opened at $122.27 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.71 and a quick ratio of 0.60. The stock has a market cap of $40.59 billion, a P/E ratio of 7.33, a price-to-earnings-growth ratio of 1.16 and a beta of 1.39. Allergan has a 12-month low of $120.68 and a 12-month high of $197.00.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Tuesday, May 14th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 2.42%. The ex-dividend date of this dividend is Monday, May 13th. Allergan’s dividend payout ratio (DPR) is 17.74%.
A number of institutional investors have recently made changes to their positions in AGN. BlackRock Inc. boosted its stake in shares of Allergan by 2.9% in the 4th quarter. BlackRock Inc. now owns 21,466,017 shares of the company’s stock valued at $2,869,149,000 after buying an additional 600,535 shares during the period. Oregon Public Employees Retirement Fund boosted its stake in shares of Allergan by 14,208.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 20,762,744 shares of the company’s stock valued at $155,000 after buying an additional 20,617,639 shares during the period. Clearbridge Investments LLC boosted its stake in shares of Allergan by 8.6% in the 1st quarter. Clearbridge Investments LLC now owns 9,167,006 shares of the company’s stock valued at $1,342,141,000 after buying an additional 726,688 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Allergan by 6.5% in the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock valued at $990,867,000 after buying an additional 410,746 shares during the period. Finally, FMR LLC boosted its stake in shares of Allergan by 42.0% in the 1st quarter. FMR LLC now owns 6,042,005 shares of the company’s stock valued at $884,611,000 after buying an additional 1,788,265 shares during the period. Institutional investors own 80.29% of the company’s stock.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Further Reading: What is the Beige Book?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.